Trialssemaglutidenovo nordiskgastric emptyingobesity

Novo Nordisk registers Phase 1 trial of high-dose semaglutide on gastric emptying

The placebo-controlled study in participants with obesity is listed as not yet recruiting, with a start date of September 25, 2026.

By Priya Raman · Science Reporter

Sep 29 08:00 ETSource: ClinicalTrials.gov

The wire

01NCT07845578 will randomize adults with obesity or overweight to subcutaneous semaglutide at a high dose or placebo to measure the effect on gastric emptying.
02Gastric emptying data bear on peri-procedural fasting guidance and on the nausea and vomiting that drive discontinuation.
03It is a Phase 1 registration only; no enrollment figures, dose levels or completion date are posted.

From the source

A Research Study Looking Into How a High Dose of s.c. Semaglutide Works With Emptying of the Stomach in People With Excess Body Weight
NCT07845578 · PHASE1 · NOT YET RECRUITING · Sponsor: Novo Nordisk A/S · Conditions: Obesity, Overweight.

Read at clinicaltrials.gov

Source URL https://clinicaltrials.gov/study/NCT07845578